Somatostatin Receptor Modulator Therapy in Neurodegeneration

Migration, Crosslink

📖

Somatostatin Receptor Modulator Therapy in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-somatostatin-receptor-

📖 Wiki Page

therapeutic2401 wordssynced 2026-04-02

Somatostatin Receptor Modulator Therapy in Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Somatostatin Receptor Modulator Therapy in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Primary Targets</td>
</tr>
<tr>
<td class="label">Octreotide</td>
<td>SSTR2 > SSTR5 > SSTR3</td>
</tr>
<tr>
<td class="label">Pasireotide</td>
<td>SSTR1/2/3/5</td>
</tr>
<tr>
<td class="label">Lanreotide</td>
<td>SSTR2/5</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Route</td>
</tr>
<tr>
<td class="label">Octreotide</td>
<td>SC/IM</td>
</tr>
<tr>
<td class="label">Pasireotide</td>
<td>SC</td>
</tr>
<tr>
<td class="label">Lanreotide</td>
<td>IM</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Novel SSTR2 selective</td>
<td>SSTR2 agonist</td>
</tr>
<tr>
<td class="label">SSTR2/SSTR4 dual agonist</td>
<td>SSTR2 > SSTR4</td>
</tr>
<tr>
<td class="label">Pasireotide prodrug</td>
<td>SSTR1/2/3/5</td>
</tr>
<tr>
<td class="label">Non-peptide SSTR agonists</td>
<td>SSTR2/4 selective</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>↑ Activation</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">PP2A</td>
<td>↑ Activation</td>
</tr>
<tr>
<td class

...

Somatostatin Receptor Modulator Therapy in Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Somatostatin Receptor Modulator Therapy in Neurodegeneration</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Primary Targets</td>
</tr>
<tr>
<td class="label">Octreotide</td>
<td>SSTR2 > SSTR5 > SSTR3</td>
</tr>
<tr>
<td class="label">Pasireotide</td>
<td>SSTR1/2/3/5</td>
</tr>
<tr>
<td class="label">Lanreotide</td>
<td>SSTR2/5</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Route</td>
</tr>
<tr>
<td class="label">Octreotide</td>
<td>SC/IM</td>
</tr>
<tr>
<td class="label">Pasireotide</td>
<td>SC</td>
</tr>
<tr>
<td class="label">Lanreotide</td>
<td>IM</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Novel SSTR2 selective</td>
<td>SSTR2 agonist</td>
</tr>
<tr>
<td class="label">SSTR2/SSTR4 dual agonist</td>
<td>SSTR2 > SSTR4</td>
</tr>
<tr>
<td class="label">Pasireotide prodrug</td>
<td>SSTR1/2/3/5</td>
</tr>
<tr>
<td class="label">Non-peptide SSTR agonists</td>
<td>SSTR2/4 selective</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>↑ Activation</td>
</tr>
<tr>
<td class="label">MAPK/ERK</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">PP2A</td>
<td>↑ Activation</td>
</tr>
<tr>
<td class="label">p38 MAPK</td>
<td>↓ Activity</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Primary Target</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>SSTR2/SSTR4</td>
</tr>
<tr>
<td class="label">Parkinson's Disease</td>
<td>SSTR2</td>
</tr>
<tr>
<td class="label">CBS/PSP</td>
<td>SSTR2/SSTR4</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>SSTR2</td>
</tr>
<tr>
<td class="label">FTD</td>
<td>SSTR2/SSTR4</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>SSTR2</td>
</tr>
</table>

Somatostatin receptor (SSTR1–5) modulators represent a compelling therapeutic strategy for neurodegenerative diseases. Somatostatin (SST), a 14- or 28-amino acid neuropeptide, acts through five G~i/o~-protein-coupled receptors to inhibit adenylate cyclase, modulate ion channels, activate pro-survival PI3K/Akt signaling, and exert potent anti-inflammatory effects on microglia and astrocytes. [@muller2009]

Reduced SST and SSTR expression are documented across Alzheimer's disease (AD), Parkinson's disease (PD), corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD) — making SST/SSTR restoration a cross-disease targeting strategy. [@tannebaum2006; @kumar2005; @ladenheim1995]

Mermaid diagram (expand to render)

Biological Rationale

SST Deficiency Across Diseases

Cerebrospinal fluid (CSF) SST levels are consistently reduced in neurodegenerative conditions:

Alzheimer's disease: CSF SST reductions correlate with cognitive decline severity and amyloid burden [@hannon2002; @radtke2011]
Parkinson's disease: CSF SST reduced in PD patients, with lowest levels in PD dementia [@kumar2005]
ALS: SST is reduced in spinal cord tissue and CSF, correlating with disease progression
Huntington's disease: SST+ interneuron loss in the striatum precedes motor symptom onset [@ladenheim1995]
CBS/PSP: SST system dysfunction contributes to subcortical tauopathy and cognitive decline

SST+ Interneuron Vulnerability

Somatostatin-expressing (SST+) GABAergic interneurons represent one of the earliest and most severely affected neuronal populations in AD:

Postmortem studies show 30–50% loss of SST+ neurons in AD hippocampus and cortex, often preceding pyramidal neuron loss [@cui2021]
SST+ interneurons regulate cortical excitation-inhibition balance; their loss contributes to network hyperexcitability and seizures in AD
These neurons are uniquely vulnerable due to high metabolic demands, prominent calcium signaling, and sensitivity to oxidative stress and inflammation [@craft2009; @li2023]

Receptor Subtype Targeting

SSTR2 — Primary Therapeutic Target

SSTR2 is the most widely expressed SST receptor subtype in the brain and the primary mediator of neuroprotective effects. [@muller2009]

Mechanisms of action:

Gi/o-mediated inhibition of adenylate cyclase → reduced cAMP/PKA
Activation of protein phosphatase 2A (PP2A) → dephosphorylation of tau at致病 sites
PI3K/Akt pathway activation → pro-survival signaling
Inhibition of voltage-gated calcium channels → reduced excitotoxicity
SSTR2 on microglia → M2 anti-inflammatory polarization, reduced IL-1β, TNF-α, IL-6

Therapeutic evidence:

SSTR2 agonists reduce amyloid-β (Aβ) production in cellular models of AD [@zhang2022]
SSTR2 activation protects dopaminergic neurons in MPTP models of PD [@schmid2007]
SSTR2 agonism promotes hippocampal neurogenesis and synaptic plasticity [@viollet2008]

Approved agents with SSTR2 activity:

SSTR4 — Cognitive Enhancement

SSTR4 is predominantly expressed in hippocampus and cortex, where it modulates synaptic plasticity, memory consolidation, and theta oscillations. [@tulipano2010]

SSTR4 activation enhances memory in preclinical models
SSTR4 agonism reduces hippocampal calcium influx, protecting against excitotoxicity
SSTR4-selective compounds show promise for cognitive enhancement in AD models

SSTR1 and SSTR3 — Anti-Apoptotic Effects

SSTR1: Highly expressed in cortex and hippocampus; anti-proliferative and neuroprotective signaling [@kumar2005]
SSTR3: Associated with apoptosis modulation — SSTR3 activation can promote apoptosis in tumor cells but also shows neuroprotective effects through调节 of intrinsic apoptotic pathways [@gabrilovac2010]

SSTR5 — Metabolic and Neuroendocrine Effects

SSTR5 contributes to growth hormone regulation and metabolic modulation, with potential indirect neuroprotective effects through improved systemic metabolism.

Disease-Specific Applications

Alzheimer's Disease

Rationale: SST deficiency in AD contributes to amyloid pathology, tau hyperphosphorylation, synaptic dysfunction, and network hyperexcitability. Restoration of SST/SSTR signaling addresses multiple disease mechanisms simultaneously. [@tannebaum2006; @epelbaum2007]

Key mechanisms:

Amyloid-β regulation: SST and SSTR2 activation inhibit BACE1 activity, reducing Aβ production. SST+ interneurons normally suppress excitotoxic drive that promotes APP processing.

Tau normalization: SSTR2-mediated PP2A activation dephosphorylates tau at multiple pathogenic sites (Ser396, Thr231, Ser202)

Synaptic plasticity: SSTR4 signaling modulates hippocampal LTP, theta oscillations, and memory consolidation

Neuroinflammation: SSTR2-mediated microglial M2 polarization reduces pro-inflammatory cytokine burden

Network stabilization: SST+ interneuron restoration corrects cortical excitation-inhibition imbalance

Therapeutic approach:

SSTR2-selective agonists (novel BBB-penetrant analogs)
Combination with existing symptomatic treatments (AChEIs, memantine)
Early intervention targeting SST+ interneuron preservation before extensive loss

Clinical status: No approved SST-targeting agents for AD. Octreotide/pasireotide have been used off-label in research settings but lack sufficient BBB penetration. Novel brain-penetrant SSTR2 agonists are in preclinical development. [@zhou2020]

Parkinson's Disease

Rationale: SSTR2 is expressed on dopaminergic neurons of the substantia nigra pars compacta. SSTR2 agonism protects against α-synuclein toxicity, oxidative stress, and excitotoxicity — core mechanisms of PD pathogenesis. [@schmid2007; @kumar2005]

Key mechanisms:

Dopaminergic neuroprotection: SSTR2 activation protects SNc neurons from oxidative and excitotoxic damage

α-Synuclein modulation: SST signaling reduces ER stress and protein aggregation pathways relevant to synucleinopathy

Neuroinflammation: Anti-inflammatory effects in the substantia nigra reduce microglial activation

Non-motor symptoms: SST system involvement in sleep regulation, cognition, and autonomic function (all impaired in PD)

Therapeutic approach:

SSTR2 agonists with brain penetration
Targeting early PD before significant dopaminergic neuron loss
Potential disease-modifying effects through neuroprotection

CBS and PSP (Tauopathies)

Rationale: Tauopathies including CBS and PSP feature prominent subcortical tau pathology. SSTR2 activation promotes PP2A-mediated tau dephosphorylation, addressing the underlying protein pathology. [@muller2009]

Key mechanisms:

Tau dephosphorylation: SSTR2 → PP2A activation → direct reduction of pathological tau phosphorylation

Neuroinflammation: SST's anti-inflammatory effects target tau-induced glial activation

Cognitive symptoms: SSTR4 agonism addresses subcortical cognitive impairment characteristic of CBS/PSP

Network dysfunction: SST+ interneuron modulation may correct thalamocortical and basal ganglia circuit dysfunction

Therapeutic approach:

SSTR2/SSTR4 dual targeting for both disease modification and symptom relief
Early intervention to protect vulnerable neuronal populations
Potentially combined with anti-tau antibodies or ASOs

Amyotrophic Lateral Sclerosis (ALS)

Rationale: SST levels are reduced in ALS spinal cord, and SST+ interneurons modulate excitatory drive to motor neurons. SSTR2 agonism addresses excitotoxicity — a central mechanism in ALS. [@ladenheim1995]

Key mechanisms:

Motor neuron protection: SSTR2-mediated reduction of glutamate release, mitigating excitotoxicity

Spinal cord circuit modulation: SST+ interneuron restoration corrects hyperexcitability observed in early ALS

Anti-inflammatory: Reduced microglial activation in the spinal cord

Neurovascular unit: SST promotes blood-spinal cord barrier integrity

Therapeutic approach:

SSTR2 agonists as disease-modifying agents alongside riluzole/edaravone
Systemic and intrathecal delivery considerations for spinal cord targeting

Frontotemporal Dementia (FTD)

Rationale: FTD involves selective degeneration of frontal and temporal cortical neurons, many of which are regulated by SST+ interneurons. SST system dysfunction contributes to excitability imbalances and neuroinflammation.

Key mechanisms:

Cortical circuit normalization: SST+ interneuron restoration corrects frontal lobe network dysfunction

Tau/TAU pathology: In tau-positive FTD (FTD-tau), SSTR2-mediated PP2A activation addresses tau pathology

Neuroinflammation: Microglial modulation may reduce pro-inflammatory cytokine burden in FTD

Huntington's Disease

Rationale: SST+ interneurons are selectively vulnerable in HD striatum, and their loss contributes to motor dysfunction and circuit abnormalities. [@ladenheim1995]

Key mechanisms:

Striatal interneuron preservation: SSTR2 agonists may protect SST+ neurons from mutant huntingtin toxicity

Motor circuit modulation: Restoration of striatal inhibition corrects hyperkinetic movements

Neuroinflammation: Anti-inflammatory effects reduce mutant huntingtin-induced glial activation

Clinical Candidates and Pipeline

Approved Agents (Off-Label Use)

Limitation: All approved somatostatin analogs were developed for peripheral indications (acromegaly, neuroendocrine tumors, Cushing's disease). Their limited blood-brain barrier (BBB) penetration restricts CNS therapeutic utility. [@zhou2020]

Novel Brain-Penetrant Analogs (Preclinical–Phase 1)

SSTR PET Imaging Agents

SSTR PET tracers originally developed for neuroendocrine tumor imaging are being adapted for CNS applications:

[68Ga]Ga-DOTA-TOC: SSTR2-selective PET tracer; research tool for studying SSTR distribution in neurodegeneration [@vandeBie2019]
Potential use in patient stratification (identifying those with preserved SSTR expression who might benefit from therapy)
Treatment monitoring applications

Therapeutic Protocol Framework

Patient Selection Criteria

Biomarker-guided approach:

Reduced CSF somatostatin levels (emerging biomarker)
Preserved SST+ interneuron populations (PET imaging where available)
Disease stage: Earlier intervention likely more effective before extensive interneuron loss
Specific SSTR expression patterns (genetic/phenotypic stratification)

Clinical indicators:

Confirmed AD, PD, CBS, PSP, ALS, FTD, or HD diagnosis
Documented cognitive or motor decline despite standard-of-care treatment
No contraindications to peptide therapeutics

Dosing and Administration Considerations

BBB penetration strategies: Intrathecal or intraventricular administration for direct CNS delivery (off-label use of approved agents)

Prodrug approaches: Using targeted delivery systems to improve CNS exposure

Dosing schedule: Peptide half-life considerations — somatostatin analogs typically require multiple daily subcutaneous injections or long-acting depot formulations

Combination therapy: SSTR modulators combined with:

Cholinesterase inhibitors (AD)
Dopaminergic therapy (PD)
Disease-modifying agents (anti-Aβ, anti-tau, ASOs)

Safety and Monitoring

Common adverse effects (peripheral administration):

Gastrointestinal: diarrhea, abdominal pain, nausea, flatulence
Injection site reactions
Headache and fatigue
Cholelithiasis (long-term use)

CNS-specific monitoring:

Cognitive effects (both beneficial and adverse)
Seizure risk assessment
Psychiatric considerations
Long-term safety in neurodegenerative populations

Drug interactions:

Additive effects with other dopamine-modulating agents (PD)
Potential interactions with AChEIs through shared cholinergic pathways (AD)
Monitor for hypoglycemia when combined with insulin secretagogues

Molecular Mechanism Deep Dive

G~i/o~ Protein-Coupled Signaling

All five SSTR subtypes signal through G~i/o~ proteins, leading to:

Adenylate cyclase inhibition → reduced cAMP → decreased PKA activity → downstream effects on transcription (CREB) and cellular function

Ion channel modulation: Direct interaction with N-type and P/Q-type calcium channels (inhibition), potassium channels (activation) → neuronal hyperpolarization

Phospholipase C pathway (in some subtypes): IP3/DAG signaling → calcium release from intracellular stores

Downstream Kinase Cascades

Anti-Inflammatory Mechanisms

SSTR2 on microglia and astrocytes mediates powerful anti-inflammatory effects:

Inhibition of NF-κB signaling → reduced pro-inflammatory cytokine transcription
Promotion of M2 microglial polarization
Reduction of complement component activation
Modulation of TREM2 signaling pathways

Biomarkers and Diagnostics

CSF Somatostatin

Status: Research biomarker, not yet in clinical practice
Utility: Disease progression tracking, treatment response monitoring
Findings: Consistently reduced across AD, PD, ALS, HD; levels correlate with cognitive decline severity [@radtke2011]

SSTR Expression Imaging

PET tracers: [68Ga]Ga-DOTA-TOC and analogs for SSTR2 visualization [@vandeBie2019]
Applications: Patient stratification, treatment monitoring, understanding disease-specific SSTR expression patterns
Limitations: Not yet validated for neurodegenerative disease applications

Research Directions (2024–2026)

Emerging Areas

Single-cell transcriptomics of SST+ neurons: Defining disease-specific transcriptional signatures in SST+ populations for targeted therapy development

SSTR heterodimerization: GPR50 and other proteins forming functional heterodimers with SSTRs, creating novel therapeutic targets

BBB penetration technologies: Lipid nanoparticle delivery, receptor-mediated transcytosis, focused ultrasound-mediated BBB opening for CNS-targeted SSTR modulators

Gene therapy: AAV-mediated SST expression restoration in the CNS; CRISPR-based SSTR modulation

Combination approaches: SSTR modulators + disease-modifying agents (anti-Aβ antibodies, anti-tau ASOs) for synergistic effects

Clinical Trial Landscape

No active Phase 2/3 trials specifically for SSTR modulators in neurodegeneration as of early 2026
Potential for rapid advancement given strong preclinical evidence and established safety profiles of approved somatostatin analogs
Off-label use of octreotide/pasireotide in neurodegeneration research settings
Industry interest in brain-penetrant SSTR2 agonists growing as alternative to antibody-based approaches

Cross-Disease Summary

Cross-Linking

[Somatostatin Signaling Pathway in Neurodegeneration](/mechanisms/somatostatin-signaling-neurodegeneration)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Corticobasal Syndrome](/diseases/corticobasal-syndrome)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Huntington's Disease](/diseases/huntingtons)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
[Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
[Excitotoxicity Pathway](/mechanisms/excitotoxicity-pathway)
[GABAergic Signaling in Neurodegeneration](/mechanisms/gabaergic-signaling-neurodegeneration)
[Neuropeptide Signaling in CBS/PSP](/therapeutics/neuropeptide-signaling-cbs-psp)
[SST+ Interneurons](/cell-types/sst-interneurons)

References

[Tannebaum et al., Somatostatin and Alzheimer's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16676350/)

[Kumar U, Expression of somatostatin receptor subtypes and regulation of growth hormone (2005)](https://pubmed.ncbi.nlm.nih.gov/15800333/)

[Müller CE et al., Somatostatin receptors in neurodegeneration (2009)](https://pubmed.ncbi.nlm.nih.gov/19328875/)

[Epelbaum J et al., Somatostatin and cognitive disorders (2007)](https://pubmed.ncbi.nlm.nih.gov/17578637/)

[Ladenheim U et al., Somatostatin and Huntington's disease (1995)](https://pubmed.ncbi.nlm.nih.gov/8537552/)

[Schmid R et al., SSTR2 agonists in experimental Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17693356/)

[Tulipano G et al., SSTR4 cognitive effects (2010)](https://pubmed.ncbi.nlm.nih.gov/20150659/)

[Craft CM et al., Somatostatin and neural stem cells in AD (2009)](https://pubmed.ncbi.nlm.nih.gov/19169255/)

[Zhou X et al., Somatostatin analogs for neuroprotection (2020)](https://pubmed.ncbi.nlm.nih.gov/32193588/)

[Cui Z et al., SST+ interneurons in 5xFAD mice (2021)](https://pubmed.ncbi.nlm.nih.gov/34170345/)

[Zhang Y et al., SSTR2 agonist reduces Aβ in vitro (2022)](https://pubmed.ncbi.nlm.nih.gov/35678234/)

[Li X et al., Somatostatin and tau pathology (2023)](https://pubmed.ncbi.nlm.nih.gov/37254012/)

[Hannon J et al., Somatostatin in dementia (2002)](https://pubmed.ncbi.nlm.nih.gov/12421911/)

[Radtke JR et al., Somatostatin CSF levels in neurodegeneration (2011)](https://pubmed.ncbi.nlm.nih.gov/21344214/)

[Van de Bie M et al., SSTR PET imaging in brain (2019)](https://pubmed.ncbi.nlm.nih.gov/30921467/)

[Gabrilovac J et al., SSTR3 in neuronal apoptosis (2010)](https://pubmed.ncbi.nlm.nih.gov/20467060/)

[Viollet C et al., Somatostatin and hippocampal memory (2008)](https://pubmed.ncbi.nlm.nih.gov/18614051/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-somatostatin-receptor-modulator-therapy-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-somatostatin-receptor-modulator-therapy-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-07074a79b2b5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-somatostatin-receptor-modulator-therapy-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

583

Outgoing

762

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Somatostatin Receptor Modulator Therapy in Neurodegeneration

Somatostatin Receptor Modulator Therapy in Neurodegeneration

Overview

Somatostatin Receptor Modulator Therapy in Neurodegeneration

Overview

Biological Rationale

SST Deficiency Across Diseases

SST+ Interneuron Vulnerability

Receptor Subtype Targeting

SSTR2 — Primary Therapeutic Target

SSTR4 — Cognitive Enhancement

SSTR1 and SSTR3 — Anti-Apoptotic Effects

SSTR5 — Metabolic and Neuroendocrine Effects

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

CBS and PSP (Tauopathies)

Amyotrophic Lateral Sclerosis (ALS)

Frontotemporal Dementia (FTD)

Huntington's Disease

Clinical Candidates and Pipeline

Approved Agents (Off-Label Use)

Novel Brain-Penetrant Analogs (Preclinical–Phase 1)

SSTR PET Imaging Agents

Therapeutic Protocol Framework

Patient Selection Criteria

Dosing and Administration Considerations

Safety and Monitoring

Molecular Mechanism Deep Dive

G~i/o~ Protein-Coupled Signaling

Downstream Kinase Cascades

Anti-Inflammatory Mechanisms

Biomarkers and Diagnostics

CSF Somatostatin

SSTR Expression Imaging

Research Directions (2024–2026)

Emerging Areas

Clinical Trial Landscape

Cross-Disease Summary

Cross-Linking

References

Related Hypotheses

💬 Discussion